This article is more than 5 years old. Information may no longer be current.

Antimetabolites successfully treat corneal neoplasia in study

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PARIS — Mitomycin-C and 5-fluorouracil either reduced or resolved corneal neoplasia in a recent case series, according to a speaker here.

"Antimetabolites, in selected cases, may be a therapeutic option for the treatment of conjunctival or corneal neoplasia," Mirsad Ibisevic, MD, said at the French Society of Ophthalmology meeting.

Dr. Ibisevic presented results from a series of 11 interventional cases performed between April 2005 and June 2007. Six cases were treated with 5-FU 1% and five were treated with mitomycin-C (MMC) 0.04%. Of those treated with 5-FU, three tumors regressed without recurrence, two tumors decreased but required surgery and one enlarged. In the five MMC cases, two tumors regressed without recurrence, two tumors decreased but required surgery and one decreased without surgery.

"In seven cases, we didn't notice any recurrence from 4 to 16 months after antimetabolite treatment with or without surgery," Dr. Ibisevic said.